（原标题：重回4000！超级赛道攻势延续） 2026年第一个交易日，A股马上迎来了开门红。沪指拉升涨超1%，时隔34个交易日，盘中重回4000点；创业板指涨超2%，科技股、金融、周期板 块纷纷上涨。 随着"新质生产力"从政策概念走向产业落地，商业航天已不再是遥不可及的题材炒作，而是正在成长为大国博弈与经济转型的硬核引擎。 2025年见证了国防军工板块的强势复苏，尤其是涵盖卫星互联网的商业航天细分赛道，在年末更是呈现出加速上攻的态势。 元旦回来赛道延续攻势，卫星产业ETF(159218)跟踪的标的指数大涨3.78%，盘中资金抢筹积极，净流入量直接创下单日新高。 这种超额收益的背后，是资金对中国航天从"试验探索"迈向"工业化量产"这一历史性跨越的敏锐捕捉。 01 2026，开门红 板块题材上，脑机接口、保险、半导体、商业航天、创新药、游戏、有色金属板块涨幅居前；海南自贸区、旅游及酒店、银行、跨境支付、猪肉 板块跌幅居前。 具体来看，脑机接口板块早盘掀起涨停潮，倍益康30cm涨停，三博脑科、美好医疗、翔宇医疗等超20股涨停。 据报道，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑 ...

整体看，A股交投气氛十分活跃，机构资金和各路游资纷纷出手，各有斩获。 数据显示，多家机构席位出现在了蓝色光标、盐湖股份、海格通信、西测测试的龙虎榜中，此外A股实 力游资章建平也出现在蓝色光标龙虎榜中，单日买入了6482.08万元，卖出了2.59亿元。 12连阳，沪指创33年最长连阳纪录，A股春季躁动行情渐入高潮！ 1月5日，A股迎来2026年首个交易日，三大指数全天高开高走，截至收盘，沪指涨1.38%，报4023.42 点，深成指涨2.24%，报13828.63点，创业板指涨2.85%，报3294.55点，科创50指数涨4.4%，报1403.41 点。与此同时，资金纷纷疯狂涌入A股，今日沪深两市合计成交额25463.47亿元，较上一个交易日放量 5011亿。 值得注意的是，沪指在2025年末已经走出11连阳的强势走势。在今日A股实现开门红之后，沪指从2025 年12月17日至2026年1月5日的12个交易日中，成功实现12连阳，创下A股1993年以来最长连阳纪录。最 近33年间A股最长连阳纪录为11天，分别在2006年以及2017-2018年出现过。A股最长连阳纪录为99天， 但彼时A股才处于起步阶段，市场体 ...

1、行情 2026年的第一个交易日，A股迎来指数集体大涨的"开门红"。 题材方面，脑机接口全天大爆发，三博脑科（20CM）、美好医疗（20CM）、岩山科技、创新医疗、南京熊猫等集体一字板，盈趣科技、翔宇 医疗（20CM）、荣泰健康、国际医学、爱朋医疗（20CM）、麦澜德（20CM）、诚益通（20CM）、伟思医疗（20CM）、迈普医学 （20CM）、博拓生物（20CM）、航天长峰、东方中科、狄耐克（20CM）、高德红外、冠昊生物（20CM）、新华医疗等先后涨停； 存储板块同样高开高走，云汉芯城（20CM）、兆易创新、恒烁股份（20CM）、普冉股份（20CM）等纷纷涨停，江波龙、香农芯创、中微公 司、开普云等涨超10%； AI应用再度走强，南兴股份3连板，利欧股份、蓝色光标（20CM）二连板，当虹科技（20CM）、引力传媒涨停，福昕软件、汉得信息、易点 天下、福石控股等集体大涨； 此外，航天板块全天小幅震荡，医疗、量子科技、算力等均有局部强势表现，海南板块大跌。 截至收盘，沪指、深成指、创业板指分别收涨1.38%、2.24%、2.85%，市场超4100股上涨，1100余股下跌，两市明显放量至2.5万亿。 2、脑机 ...

Core Viewpoint - The A-share market experienced a strong opening on the first trading day of the new year, with significant gains across major indices and a notable increase in trading volume [1][6]. Market Performance - On January 5, the Shanghai Composite Index rose by 1.38%, reclaiming the 4000-point mark, marking a 12-day consecutive rise, the longest since March 1992 [1][3]. - The Shenzhen Component Index increased by 2.24%, the ChiNext Index by 2.85%, and the Northbound 50 Index by 1.80% [1]. - Total trading volume across the Shanghai, Shenzhen, and North exchanges reached 25,672 billion yuan, an increase of 5,015 billion yuan compared to the previous trading day [1]. Historical Context - The 12-day consecutive rise of the Shanghai Composite Index from December 17, 2025, to January 5, 2026, set a new record since March 1992, where previous records included three instances of 11 consecutive days [3][4]. Sector Highlights - The brain-computer interface sector saw a surge, with nearly 30 stocks, including BeiYikang and MeiHao Medical, hitting the daily limit [4]. - Innovative drug concept stocks collectively surged, with GuanHao Biological reaching a 20% limit up, indicating sustained interest in this sector [4]. - The insurance sector performed strongly, with Xinhua Insurance and China Pacific Insurance both reaching historical highs during the trading session [4]. - The storage chip sector also experienced significant gains, with stocks like JiangBolong and XiangNong Chip rising sharply, reflecting renewed momentum in the technology sector [4]. - Other sectors such as gaming, commercial aerospace, and military equipment also showed robust performance during the trading day [5].

Core Viewpoint - The brain-computer interface (BCI) technology is transitioning from experimental research to commercial application, with significant advancements expected in the coming years, particularly driven by Neuralink's plans for mass production and automated surgical processes [1][3][5]. Group 1: Company Developments - Neuralink plans to begin large-scale production of its brain-computer interface devices in 2026, with a focus on streamlined and automated surgical procedures [1]. - As of September 2025, 12 individuals have received Neuralink's device implants, accumulating over 15,000 hours of usage [1]. - The company has demonstrated that clinical trial participants can control physical devices, such as robotic arms, using the BCI technology [1]. Group 2: Market Response - On the first trading day of 2026, BCI-related stocks surged, with the index rising over 12% and multiple stocks hitting their daily limit [2]. - The market's reaction reflects strong expectations for the commercialization of BCI technology [2]. Group 3: Industry Trends - The BCI industry is poised for unprecedented growth, with 2025 being identified as a pivotal year for development in China, supported by policy, capital investment, and technological breakthroughs [3][8]. - The Chinese government has included BCI technology in its 14th Five-Year Plan, indicating a commitment to fostering this emerging industry [3][8]. - Various local governments are actively developing BCI industries, with specific plans and goals set for clinical trials and product applications by 2030 [3]. Group 4: Technological Advancements - Neuralink aims to enhance the bandwidth of human-machine communication, with future goals including direct thought-to-speech translation and visual restoration for the visually impaired [4]. - The global BCI landscape is characterized by competition between the U.S. and China, with multiple technological pathways being explored [5]. Group 5: Challenges and Opportunities - Despite impressive clinical results, invasive BCI technologies face challenges related to biocompatibility and long-term stability [6]. - Regulatory and ethical considerations are significant barriers to widespread adoption, particularly concerning safety and privacy [6]. - The high costs associated with BCI technology and the need for specialized medical teams for implantation are limiting factors for market penetration [6]. Group 6: Educational and Regulatory Developments - China is enhancing its clinical trial approval processes, potentially reducing the time required for BCI medical applications to reach the market [7]. - Educational initiatives, such as the establishment of a dedicated BCI program at Tianjin University, are being implemented to cultivate talent in this interdisciplinary field [7]. Group 7: Market Potential - The healthcare sector is projected to dominate the BCI application market, accounting for 56% of the total market size, with potential market space in serious medical applications estimated between $15 billion and $85 billion [8]. - The consumer healthcare segment, including health monitoring and cognitive enhancement, is expected to reach a market size of $25 billion to $60 billion [8].

Market Overview - The market experienced a strong opening with 108 stocks hitting the daily limit, and the sealing rate reached 81%, indicating robust investor sentiment [1] - The ChiNext index led the gains, while the Shanghai Composite Index returned above 4000 points, marking a 12-day consecutive rise [1] - Total trading volume in the Shanghai and Shenzhen markets reached 2.55 trillion, an increase of 501.1 billion from the previous trading day [1] Stock Performance - Notable stocks included Fenglong Co., which achieved a 7-day limit, and Leike Defense with a 4-day limit [1] - The market saw over 4100 stocks rising, with sectors like brain-computer interfaces, innovative pharmaceuticals, insurance, and storage chips leading the gains [1] - Conversely, sectors such as Hainan Free Trade Zone, tourism hotels, pork, and banking faced declines [1] Hot Topics and Trends - The brain-computer interface sector surged following Elon Musk's announcement that Neuralink would begin large-scale production in 2026, leading to significant stock price increases in related companies [6] - The commercial aerospace sector remains popular, with companies like Leike Defense and China Satellite Communications achieving consecutive limit-ups [5] - The semiconductor industry is also performing well, with TSMC increasing prices for advanced processes due to high demand, and several companies in the sector reporting significant gains [7] Investment Opportunities - The insurance sector showed strong performance, with major companies like China Life and Ping An reporting new single premium growth rates between 40-60% [8] - The overall market sentiment remains positive, with a high number of stocks hitting daily limits, although concerns about the sustainability of this momentum exist [9] - The potential for further gains in sectors like brain-computer interfaces and commercial aerospace is supported by recent policy developments and market interest [6][5]

Market Overview - The A-share market experienced a strong opening on the first trading day of 2026, with the Shanghai Composite Index rising over 1% to close at 4023.42 points, while the Shenzhen Component Index and the ChiNext Index increased by 2.24% and 2.85%, respectively [1] - The STAR 50 Index led the market with a remarkable gain of 4.41%, indicating a significant bullish sentiment [1] - Market trading activity surged, with total turnover reaching 2.57 trillion yuan, an increase of approximately 500 billion yuan from the previous trading day, reflecting the inflow of new capital [1] Sector Performance - The technology and healthcare sectors were the main drivers of the market rally, with the media, pharmaceutical, and electronics sectors all rising over 3.5% [1] - Non-bank financials, particularly insurance, and the computer sector also showed considerable gains, highlighting the two core investment themes: hard technology growth (AI, semiconductors, brain-computer interfaces) and innovative pharmaceuticals [1] Key Drivers of Growth - The surge in the pharmaceutical sector was primarily triggered by the announcement from Elon Musk's Neuralink regarding the large-scale production of brain-computer interface devices starting in 2026, which ignited investor interest in human-computer interaction technologies [2] - The innovative drug sector reached a milestone with 76 new drugs approved in 2025, generating over 130 billion yuan in licensing deals, showcasing the international recognition of domestic pharmaceutical companies [3] - The technology sector's growth was fueled by the ongoing AI wave and the anticipated demand for hardware, particularly in the semiconductor industry, with projections of a 50% increase in DRAM contract prices in Q1 2026 [3] Financial Sector Insights - The non-bank financial sector, particularly insurance stocks, saw significant gains, with companies like China Pacific Insurance and New China Life reaching historical highs, supported by favorable regulatory policies aimed at enhancing the health insurance market [4] - The combination of a declining interest rate environment and improved product attractiveness has led to renewed investor interest in insurance products, which possess both defensive and growth characteristics [4] Market Outlook - The strong market performance sets a positive foundation for the spring market of 2026, with expectations of sustained high-risk appetite driven by favorable policies, clear industry trends, and ample liquidity [4] - The dual themes of "technology + healthcare" are expected to continue leading the market, with specific focus on brain-computer interfaces, innovative drugs, AI computing power, and storage chips [4]

Group 1: Neuralink Developments - Neuralink plans to increase brain-computer interface (BCI) output in 2026, transitioning to nearly fully automated surgeries[3] - As of January 5, 2026, the Wande BCI Index rose by 10.54%, with companies like Sanbo Neuroscience and Meihua Medical hitting the daily limit[3] - Neuralink aims to exceed 25,000 electrodes by 2028, expanding applications to treat mental disorders and integrating with AI[3] Group 2: Policy and Market Support - Multiple government departments in China are supporting BCI development, with the National Healthcare Security Administration including BCI in medical insurance as of March 2025[3] - The "14th Five-Year Plan" lists BCI as one of the six future industries, aiming for significant breakthroughs by 2027[3] - As of December 2025, the BCI sector in China has seen 24 financing rounds, totaling over 5 billion yuan, with a record single financing of 350 million yuan[3] Group 3: Clinical and Commercial Progress - Domestic BCI projects are moving from exploration to clinical stages, with significant trials completed in 2025[3] - The first long-term invasive BCI clinical trial in China was completed in March 2025, marking a milestone in the field[3] - Companies like Sanbo Neuroscience and Meihua Medical are highlighted as key players in the BCI industry, with potential for accelerated commercialization[3]

Group 1 - The medical device sector experienced a significant increase of 5.5% on January 5, with JinHao Medical leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] - Notable individual stock performances included JinHao Medical with a closing price of 38.23, up 20.03%, and BoTuo Bio with a closing price of 45.34, also up 20.01% [1] Group 2 - The medical device sector saw a net inflow of 1.678 billion yuan from institutional investors, while retail investors experienced a net outflow of 644 million yuan [2] - The top individual stock in terms of net inflow was AiPeng Medical, with a net inflow of 1.57 million yuan, representing 25.59% of its trading volume [3] - Conversely, major outflows were observed in stocks like MaiRui Medical, which had a net outflow of 91.39 million yuan from retail investors, accounting for 2.74% of its trading volume [3]

| 300143 | 盈康生 命 | 15.18 | 7.38 | 10.23 | 11.38 | 11.28 | | --- | --- | --- | --- | --- | --- | --- | | | 泰和科 | | | | | | | 300801 | 技 | 15.49 | 20.84 | 28.75 | 31.91 | 10.98 | （文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 五日均线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 920199 | 倍益康 | 29.98 | 12.94 | 37.83 | 44.96 | 18.85 | | 920925 | 锦好医 疗 | 20.03 | 19.58 | 33.00 | 38.23 | 15.84 | | 688580 | 伟思医 疗 | 20.00 | 7.33 | 50.50 | 58.08 | 15.01 | | 300430 | 诚益通 ...